Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
DRUG: Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
Part 1: Safety and tolerability of gefitinib 250 mg in combination with radiotherapy (incidence of DLTs)|Parts 2 and 3: Safety and tolerability of gefitinib in combination with 5-FU, LV and radiotherapy
Parts 2 and 3:|Objective tumour response rate a week before surgery (CR and PR, RECIST criteria).|Objective histological response rate in dissected GC specimens taken at surgery, estimated using Evans/Pisters scores|Exploratory outcome: Parts 2 and 3: sVEGF levels, EGFR activation, Biomarkers such as cyclin D1, IL-1, GI-associated TOP2A, GAS, EST AA552509
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer